Study of COPD Subgroups and Biomarkers

Summary

SPIROMICS I, SPIROMICS II, and SPIROMICS III are longitudinal observational studies of Chronic Obstructive Pulmonary Disease (COPD) cohort.

SPIROMICS I had two primary aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not COPD is getting worse and to provide new ways of testing whether a new treatment is working.

SPIROMICS II had three primary aims: (1) To define the natural history of "smokers with symptoms despite preserved spirometry" and characterize the airway mucus abnormalities underlying this condition; (2) To determine the radiographic precursor lesion(s) for emphysema and identify the molecular phenotypes underlying airway disease and emphysema; (3) To advance understanding of the biology of COPD exacerbations through analysis of predisposing baseline phenotypes, exacerbation triggers and host inflammatory response.

SPIROMICS III has three primary aims: (1) To identify the main forms of smoking-related airway disease that are caused by pathological airway mucus, their biological underpinnings, and their physiological significance; (2) To identify longitudinal trajectories in established and novel CT measures of emphysema, test how they predict COPD progression, and define their underlying biology; (3) To identify environmental and social determinants of health that impact disease severity and progression and their influence on lung structure, biology, and health disparities in COPD.

Conditions

• COPD
• Chronic Obstructive Pulmonary Disease
• Chronic Bronchitis
• Emphysema

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• COPD Foundation

  collaborator OTHER

• Columbia University

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• National Jewish Health

  collaborator OTHER

• Temple University

  collaborator OTHER

• University of Alabama at Birmingham

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• University of California, San Francisco

  collaborator OTHER

• University of Illinois at Chicago

  collaborator OTHER

• University of Iowa

  collaborator OTHER

• University of Michigan

  collaborator OTHER

• University of Utah

  collaborator OTHER

• Wake Forest University

  collaborator OTHER

• University of North Carolina, Chapel Hill

  lead OTHER

Principal Investigators

• David Couper, PhD · University of North Carolina, Chapel Hill

• Graham Barr, PhD, MD · Columbia University

• Robert Paine, MD · University of Utah

• Eric Hoffman, MD · University of Iowa

• Prescott Woodruff, MD · University of California at San Francisco

• Igor Barjaktarevic, MD · University of California at Los Angeles

• MeiLan Han, MD · University of Michigan

• Claudia Onofrei, MD, MSc · National Jewish Health

• Alejandro Cornellas, MD · University of Iowa

• Nathaniel Marchetti, DO · Temple University

• J. Michael Wells, MD · University of Alabama at Birmingham

• Nadia Hansel, MD · Johns Hopkins University

• Jerry Krishnan, MD · University of Illinois at Chicago

• Jessica Bon, MD, MS, ATSF · Wake Forest University

• Robert Kaner, MD · Weill Medical College of Cornell University

• Victor Ortega, MD, PhD · Mayo Clinic

• Christopher Cooper, MD, PhD · University of California at Los Angeles

• Neil Alexis, PhD · University of North Carolina, Chapel Hill

• Sanjiv Shah · Northwestern University

• Joao Lima, MD, MBA · Johns Hopkins University

Eligibility

Min Age

40 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2010-11-30

Primary Completion

2031-06-17

Completion

2031-06-17

Countries

• United States

Study Locations